Fred Fox,
Ethicist,
BioMedical Research Institute -- BioMed IRB
Fred Fox was recruited to the BioMed IRB two decades ago because he was willing to volunteer his time supporting the ethical oversight of medical research, and, had a professional background in the overlap of research, medicine and law. The BioMed IRB is part of the BioMedical Research Institute of America, which was founded by volunteers from bioengineering, medicine and education in 1955. The BioMed IRB provides oversight, since 1980, for researchers outside of hospitals or academic systems. At the request of investigators, Fred Fox also chaired the Stem Cell Research Oversight (SCRO) panels for trailblazing sponsors in need of independent ethical oversight. Fred is a California attorney and was general counsel in past decades for developers of scientific instrumentation and providers of health care insurance products.
Answering Questions About Obstacles, Especially Financial and Regulatory, to Evidence-Gathering for your Research to become a Standard of Care Practice
Tuesday, 22 April 2014 at 11:15
Add to Calendar ▼2014-04-22 11:15:002014-04-22 12:15:00Europe/LondonAnswering Questions About Obstacles, Especially Financial and Regulatory, to Evidence-Gathering for your Research to become a Standard of Care PracticeClinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California, USASELECTBIOenquiries@selectbiosciences.com
To start the presentation off, Fred Fox will present a "hypothetical" case study. If there are no specific questions from participants, then a survey set of questions will be posed and addressed by Mr. Fox, following the common elements for any stem cell research and development project.
The case study is loosely based on the elements from the real news report of an academic team, in China, using urine to collect cells and then induce stem cells later trained to be stem cells for a dental repair. [that news report is available from this link http://www.bbc.co.uk/news/health-23492425]. What are the obstacles in collecting cells, in the case study, from urine? What are the obstacles in GTP for storing, inducing stem cells and having a stem cell line for research and development, in general? Which obstacles are specific to using a patients own stem cells for any specific and near instant medical procedures? What other diagnostic or treatment obstacles should be addressed if missing teeth are to be replaced or, in a variation on the hypothetical case study, if patients are to bypassing "implants" with titanium screws for 3D-printed biomaterials seeded with stem cells to repair teeth in place.
What are the specific obstacles, especially financial or regulatory, to using induced stem cells in dental repair studies on the path of commercialization, from clinical investigations through a standard of care with reimbursement codes?
Questions from Delegates are Welcome.
Add to Calendar ▼2014-04-21 00:00:002014-04-22 00:00:00Europe/LondonClinical Translation of Stem Cells 2014Clinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-04-22 11:15:002014-04-22 12:15:00Europe/LondonAnswering Questions About Obstacles, Especially Financial and Regulatory, to Evidence-Gathering for your Research to become a Standard of Care PracticeClinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California, USASELECTBIOenquiries@selectbiosciences.com
